In the News Articles

Newman CB, Preiss D, Tobert JA et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 2018:Atv0000000000000073.

http://www.ncbi.nlm.nih.gov/pubmed/?term=30580575

Yebyo HG, Aschmann HE, Puhan MA. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. Annals of internal medicine 2018.

http://www.ncbi.nlm.nih.gov/pubmed/?term=30508425

Monami M, Sesti G, Mannucci E PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes Metab. 2018 Nov 28. doi: 10.1111/dom.13599.

https://www.ncbi.nlm.nih.gov/pubmed/30485622

Morville T, Dohlmann T, Kuhlman AB et al. Glucose homeostasis in statin users - the LIFESTAT study. Diabetes/metabolism research and reviews 2018:e3110.

http://www.ncbi.nlm.nih.gov/pubmed/?term=30517978

Malhotra K, Safouris A, Goyal N et al. Association of statin pretreatment with collateral circulation and final infarct volume in acute ischemic stroke patients: A meta-analysis. Atherosclerosis 2019; 282:75-79.

http://www.ncbi.nlm.nih.gov/pubmed/?term=30708178

Charles ED, Neuschwander-Tetri BA, Frias JP, Kundu S, Luo Y, Tirucherai GS, Christian R. Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Obesity. 2019;27:41-49.

https://www.ncbi.nlm.nih.gov/pubmed/30520566

Chen, S-J, Chuang S-Y, Chang H-Y, Pan W-H. Energy intake at different times of the day: Its association with elevated total and LDL cholesterol levels. Nutr Metab Cardiovas Dis. 2019.

https://doi.org/10.1016/j.numecd.2019.01.003

Navar AM, Roe MT, White JA et al. Medication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes 2019; 12:e005041.

http://www.ncbi.nlm.nih.gov/pubmed/?term=30630361

Bhatt DL, Steg G, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22 DOI: 10.1056/NEJMoa1812792.

https://www.nejm.org/doi/full/10.1056/NEJMoa1812792

Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022-1032.

https://www.nejm.org/doi/full/10.1056/NEJMoa1803917

Ference BA, Ray KK, Catapano AL, et al. Mendelian Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med. 2019;380:1033-1042.

https://www.nejm.org/doi/full/10.1056/NEJMoa1806747

Fogacci F, Banach M, Mikhailidis DP et al. Safety of Red Yeast Rice Supplementation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacol Res. 2019; 143:1-16.

http://www.ncbi.nlm.nih.gov/pubmed/?term=30844537

Shin J, Chung JW, Jang HS et al. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials. Eur J Prev Cardiol 2019:2047487319830503.

http://www.ncbi.nlm.nih.gov/pubmed/?term=30782002

Preston Mason R. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. Curr Atheroscler Rep 2019; 21:2.

http://www.ncbi.nlm.nih.gov/pubmed/?term=30637567

Bhatt DL, Steg G, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.

https://www.nejm.org/doi/full/10.1056/NEJMoa1812792